List All Pediatric Studies Trials

Pediatric Studies

 

Seneca Valley Virus-001 for Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features (COG-ADVL0911)
A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Investigator: Julie Park, MD;   Conditions: Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor, Kidney Cancer, Neuroblastoma, Retinoblastoma, Sarcoma;    Status: Closed;   Study ID: NCT01048892

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia (COG ADVL0413)
A Phase I study of the Raf kinase and receptor tyrosine kinase inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in children with refractory solid tumors or refractory leukemias

Investigator: Julie Park, MD;   Conditions: Refractory solid tumors , Refractory leukemias;    Status: Closed;   Study ID: NCT00343694

Cord Blood Cell Infusion Post Chemotherapy for AML (2584)
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Induction Chemotherapy (FLAG) in Patients with Relapsed/Refractory AML

Investigator: Colleen Delaney, MD, MSc;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia;    Status: Recruiting;   Study ID: NCT01701323

T Cell Depleted Donor Transplant for Preventing Graft-Versus-Host Disease (2660)
A Phase II Study of Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

Investigator: Marie Bleakley, MD;   Conditions: Leukemia;    Status: Recruiting;   Study ID: NCT01858740

Pamidronate Post Transplant for Pediatric Patients (9223)
Prevention of Bone Loss after Pediatric Hematopoietic Cell Transplantation

Investigator: K.Scott Baker;   Conditions: Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT02074631

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT-01)
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma using Autologous T-cells lentivirally transduced to express CD171-specific Chimeric Antigen Receptors

Investigator: Julie Park, MD;   Conditions: Neuroblastoma;    Status: Recruiting;   Study ID: NCT02311621

Combination of the PARP Inhibitor, Niraparib and Temozolomide for Previously Treated, Incurable Ewing Sarcoma (SC-6015)
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients with Previously Treated, Incurable Ewing Sarcoma

Investigator: Doug Hawkins, MD;   Conditions: Childhood Cancers, Miscellaneous; Sarcoma; Solid Tumors; Sarcoma, Ewing;    Status: Recruiting;   Study ID: NCT02044120

The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients with Refractory or Recurrent Brain Tumors
The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients with Refractory or Recurrent Brain Tumors

Investigator: Sarah Leary;   Conditions: Brain Cancer; Central Nervous System (CNS); Childhood Cancers, Miscellaneous; Solid Tumors; Neoplasms;    Status: Recruiting;   Study ID: NCT02015728

Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors
Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors

Investigator: Sarah Leary;   Conditions: Brain Cancer; Central Nervous System (CNS); Childhood Cancers, Miscellaneous; Solid Tumors; Neoplasms;    Status: Recruiting;   Study ID: NCT01677741

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Investigator: Doug Hawkins, MD;   Conditions: Hematologic Malignancies; Leukemia; Lymphoproliferative Disorders; Childhood Cancers, Miscellaneous; Leukemia, Lymphoid; Immunoproliferative Disorders;    Status: Closed;   Study ID: NCT01142427

Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Investigator: Sarah Leary;   Conditions: Glioma; Childhood Cancers, Miscellaneous; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial;    Status: Recruiting;   Study ID: NCT01182350

A Phase I Dose Escalation Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors including Tumors of the Central Nervous System
A Phase I Dose Escalation Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors including Tumors of the Central Nervous System

Investigator: Sarah Leary;   Conditions: Central Nervous System (CNS); Childhood Cancers, Miscellaneous; Solid Tumors; Neoplasms;    Status: Recruiting;   Study ID: NCT01751308

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)
A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine

Investigator: K.Scott Baker;   Conditions: Leukemia, Acute Myeloid (AML); Anemia, Aplastic; Fanconi Anemia; Hematologic Malignancies; Leukemia; Childhood Cancers, Miscellaneous; Myelodysplastic Syndromes (MDS); Leukemia, Myeloid; Neoplasms; Anemia; Preleukemia; Bone Marrow Diseases;    Status: Recruiting;   Study ID: NCT02143830

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

Investigator: Doug Hawkins, MD;   Conditions: Hematologic Malignancies; Leukemia; Lymphoproliferative Disorders; Childhood Cancers, Miscellaneous; Leukemia, Lymphoid; Immunoproliferative Disorders;    Status: Recruiting;   Study ID: NCT01406756

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Investigator: Kasey Leger, MD;   Conditions: Acute Lymphoblastic Leukemia;    Status: Recruiting;   Study ID: NCT02112916

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

Investigator: Doug Hawkins, MD;   Conditions: Glioma; Childhood Cancers, Miscellaneous; Solid Tumors; Neuroectodermal Tumors; Ependymoma;    Status: Recruiting;   Study ID: NCT01096368

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma
A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age

Investigator: Doug Hawkins, MD;   Conditions: Medulloblastoma; Childhood Cancers, Miscellaneous; Solid Tumors;    Status: Recruiting;   Study ID: NCT02017964

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Investigator: Doug Hawkins, MD;   Conditions: Central Nervous System (CNS); Childhood Cancers, Miscellaneous; Solid Tumors; Neoplasms, Germ Cell and Embryonal;    Status: Recruiting;   Study ID: NCT01602666

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

Investigator: Doug Hawkins, MD;   Conditions: Childhood Cancers, Miscellaneous; Sarcoma; Solid Tumors; Sarcoma, Ewing;    Status: Closed;   Study ID: NCT01231906

Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Investigator: Doug Hawkins, MD;   Conditions: Lymphoma, Hodgkin; Lymphoma; Childhood Cancers, Miscellaneous; Solid Tumors;    Status: Recruiting;   Study ID: NCT02166463

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas. (BOLD 113)
ADVL1314, A Phase 1 Study Of Eribulin Mesylate (E7389, IND #116,292), A Novel Microtubule Targeting Chemotherapeutic Agent In Children With Refractory Or Recurrent Solid Tumors (Excluding CNS), Including Lymphomas

Investigator: Doug Hawkins, MD;   Conditions: Lymphoma; Childhood Cancers, Miscellaneous; Solid Tumors;    Status: Recruiting;   Study ID: NCT02171260

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma

Investigator: Julie Park, MD;   Conditions: Childhood Cancers, Miscellaneous; Neuroblastoma; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial;    Status: Recruiting;   Study ID: NCT01711554

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Investigator: Doug Hawkins, MD;   Conditions: Childhood Cancers, Miscellaneous; Sarcoma; Solid Tumors; Sarcoma, Ewing;    Status: Recruiting;   Study ID: NCT02306161

Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Investigator: Doug Hawkins, MD;   Conditions: Lymphoma, Burkitt's; Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Childhood Cancers, Miscellaneous; Lymphoma, Non-Hodgkin (NHL); Leukemia, Lymphoid; Immunoproliferative Disorders;    Status: Closed;   Study ID: NCT01595048

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Phase II Study of everolimus for recurrent or progressive low-grade gliomas in children

Investigator: Sarah Leary;   Conditions: Brain Cancer; Glioma; Childhood Cancers, Miscellaneous; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Neuroectodermal Tumors;    Status: Recruiting;   Study ID: NCT01734512

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
ANBL1232 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study

Investigator: Julie Park, MD;   Conditions: Childhood Cancers, Miscellaneous; Neuroblastoma; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Ganglioneuroblastoma; Neoplasms, Neuroepithelial;    Status: Recruiting;   Study ID: NCT02176967

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
ADVL1315, A PHASE 1 STUDY OF THE VEGF RECEPTOR TYROSINE KINASE INHIBITOR AXITINIB (INLYTA, IND# 123101) IN CHILDREN WITH RECURRENT OR REFRACTORY SOLID TUMORS

Investigator: Julie Park, MD;   Conditions: Childhood Cancers, Miscellaneous; Solid Tumors;    Status: Recruiting;   Study ID: NCT02164838

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Treatment of Children with All Stages of Hepatoblastoma

Investigator: Doug Hawkins, MD;   Conditions: Liver Cancer; Childhood Cancers, Miscellaneous; Solid Tumors;    Status: Recruiting;   Study ID: NCT00980460

Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
An Open Label, Expanded Access Protocol Using 131I - Metaiodobenzylguanidine (131I-MIBG) Thearpy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Investigator: Julie Park, MD;   Conditions: Childhood Cancers, Miscellaneous; Neuroblastoma; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Neoplasms, Neuroepithelial; Pheochromocytoma; Paraganglioma;    Status: Recruiting;   Study ID: NCT01838187

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma

Investigator: Julie Park, MD;   Conditions: Childhood Cancers, Miscellaneous; Neuroblastoma; Solid Tumors;    Status: Recruiting;   Study ID: NCT02030964

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

Investigator: Doug Hawkins, MD;   Conditions: Childhood Cancers, Miscellaneous; Sarcoma; Solid Tumors; Sarcoma, Synovial; Liposarcoma;    Status: Recruiting;   Study ID: NCT02180867

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase I study of CDK 4-6 inhibitor PD-0332991 in children with recurrent, progressive or refractory central nervous system tumors

Investigator: Sarah Leary;   Conditions: Brain Cancer; Central Nervous System (CNS); Glioma; Medulloblastoma; Childhood Cancers, Miscellaneous; Solid Tumors; Meningioma; Neoplasms; Glioblastoma; Neuroectodermal Tumors;    Status: Recruiting;   Study ID: NCT02255461

Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E- or BRAF Ins T mutant Brain Tumors

Investigator: Sarah Leary;   Conditions: Brain Cancer; Glioma; Childhood Cancers, Miscellaneous; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms;    Status: Recruiting;   Study ID: NCT01748149

Study of BLZ-100 in Pediatric Subjects With CNS Tumors
A Phase 1 Dose-Escalation And Expansion Study Of BLZ-100 In Pediatric Subjects With Primary Central Nervous System Tumors

Investigator: Sarah Leary;   Conditions: Central Nervous System (CNS); Childhood Cancers, Miscellaneous; Solid Tumors; Neoplasms;    Status: Recruiting;   Study ID: NCT02462629

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)

Investigator: Doug Hawkins, MD;   Conditions: Hematologic Malignancies; Lymphoma; Lymphoproliferative Disorders; Childhood Cancers, Miscellaneous; Lymphoma, Non-Hodgkin (NHL); Immunoproliferative Disorders;    Status: Recruiting;   Study ID: NCT01979536

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD

Investigator: Doug Hawkins, MD;   Conditions: Leukemia, Childhood Cancers;    Status: Recruiting;   Study ID: NCT01371981

SF1126 for Relapsed or Refractory Neuroblastoma (NANT 2014-01)
Phase I Study of SF1126 for Patients with Relapsed or Refractory Neuroblastoma

Investigator: Julie Park, MD;   Conditions: Neuroblastoma, Neuroectodermal Tumors,;    Status: Recruiting;   Study ID: NCT02337309

mTOR Inhibitor Sirolimus for Desmoid-Type Fibromatosis (SC-6016)
A Pilot Study Evaluating the use of the mTOR Inhibitor Sirolimus in Children and Young Adults with Desmoid-Type Fibromatosis

Investigator: Doug Hawkins, MD;   Conditions: Pediatric Cancers, Fibroma; Desmoid Tumor;    Status: Recruiting;   Study ID: NCT01265030

Arsenic Trioxide and All-Trans Retinoic Acid for Newly Diagnosed Acute Promyelocytic Leukemia (AAML1331)
AAML1331, A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Investigator: Todd Cooper;   Conditions: Leukemia, Acute Myeloid (AML); Leukemia, Promyelocytic, Acute (APL);    Status: Recruiting;   Study ID: NCT02339740

Nivolumab and Ipilimumab for Recurrent or Refractory Solid Tumors (ADVL1412)
A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Investigator: Julie Park, MD;   Conditions: Pediatric Cancers; Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT02304458

Blinatumomab in First Relapse of B-Lymphoblastic Leukemia (AALL1331)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Investigator: Rebecca Gardner, MD;   Conditions: Pediatric Cancers; Acute Lymphoblastic Leukemia (ALL); Lymphoma;    Status: Recruiting;   Study ID: NCT02101853

131I-MIBG vs. 131I-MIBG with Vincristine and Irinotecan vs. 131I-MIBG with Vorinistat for Neuroblastoma (NANT 2011-01)
Study of Single Agent 131I-MIBG, 131I-MIBG with Vincristine and Irinotecan, or 131I-MIBG with Vorinostat for Resistant/Relapsed Neuroblastoma

Investigator: Julie Park, MD;   Conditions: Pediatric Cancers; Neuroblastoma;    Status: Recruiting;   Study ID: NCT02035137

Crizotinib + Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ADVL1212)
A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)

Investigator: Julie Park, MD;   Conditions: Pediatric Cancers; Hematologic Malignancies; Lymphoma; Lymphoproliferative Disorders;    Status: Recruiting;   Study ID: NCT01606878

Lenalidomide for Pilocytic Astrocytomas and Optic Pathway Gliomas (ACNS1022)
A Phase II Randomized Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Investigator: Doug Hawkins, MD;   Conditions: Pediatric Cancers; Glioma; Neuroblastoma;    Status: Recruiting;   Study ID: NCT01553149

Evaluation of Stem Cell Transplant Depleted of T Cell Receptors (9311)
Phase 1/2 Study of CaspaCide T Cells from an HLA-Partially Matched Family Donor after Negative Selection of TCR aß+ T Cells in Pediatric Patients Affected by Hematological Disorders

Investigator: Ann Woolfrey, MD;   Conditions: Leukemia, Acute Lymphoblastic (ALL); Acute Myeloid (AML); Hematologic Malignancies; Immunodeficiency Syndromes;    Status: Recruiting;   Study ID: NCT02065869

Dinutuximab in Combination with Sargramostim for Recurrent Osteosarcoma (AOST1421)
A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody in Combination with Sargramostim in Patients with Recurrent Osteosarcoma

Investigator: Doug Hawkins, MD;   Conditions: Lung Cancer; Pediatric Cancers; Sarcoma; Osteosarcoma;;    Status: Recruiting;   Study ID: NCT02484443

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection for Children with Cancer (ACCL1034)
ACCL1034, Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLA-BSI) and Acquisition of Multi-Drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic HCT

Investigator: Doug Hawkins, MD;   Conditions: Leukemia, Hematologic Malignancies, Pediatric Cancers;    Status: Recruiting;   Study ID: NCT01817075